Tag Archives: Geulah Livshits

Chardan Capital Believes Iovance Biotherapeutics Inc (NASDAQ: IOVA) Still Has Room to Grow

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report) today and set a price target of $30. The company’s shares closed yesterday at $17.83, close to its 52-week high of $18.25. Livshits

Intellia Therapeutics (NTLA) Gets a Buy Rating from Chardan Capital

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target of $57.50. The company’s shares opened today at $14.89. Livshits wrote: “We see the Alnylam

Tocagen Inc (TOCA) Receives a Buy from Chardan Capital

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Tocagen Inc (TOCA – Research Report), with a price target of $10. The company’s shares closed yesterday at $8.82. According to TipRanks.com, Livshits is a

Chardan Capital Sticks to Their Hold Rating for Vascular Biogenics (VBLT)

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Hold rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.21. Livshits observed: “We understand the colon

Tocagen Inc (TOCA) Received its Third Buy in a Row

After Cantor Fitzgerald and H.C. Wainwright gave Tocagen Inc (NASDAQ: TOCA) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Tocagen Inc today and set a

Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row

After Piper Jaffray and Needham gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits maintained a Buy rating on Crispr Therapeutics AG yesterday and set